Sanofi (SNY)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Paul Hudson | CEO & Director | 4.01M | -- | 1967 |
| Mr. François-Xavier Roger | Executive VP & CFO | -- | -- | 1962 |
| Ms. Madeleine Roach | Executive VP & Head of Business Operations | -- | -- | 1984 |
| Mr. Laurent Gilhodes | Principal Accounting Officer and Vice President of Corporate Accounting | -- | -- | -- |
| Dr. Josephine Fubara | Chief Science Officer of Consumer Health Care | -- | -- | -- |
| Eva Schaefer-Jansen | Head of Investor Relations | -- | -- | -- |
| Mr. Dante Beccaria | Global Compliance Officer & VP | -- | -- | -- |
| Mr. Roy Papatheodorou | Executive VP & General Counsel | -- | -- | 1978 |
| Mr. Josep Catlla | Head of Communications | -- | -- | -- |
| Mr. Pierre Chancel | Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | -- | -- | 1957 |
Sanofi
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 86,088
Description
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Corporate Governance
Recent Events
- Apr 04, 2024S-8: Offering RegistrationsSee Full Filing
- Mar 20, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 23, 202420-F: Periodic Financial ReportsSee Full Filing
- Feb 15, 20246-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 01, 20246-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Upcoming Events Information Not Available